SCHEMBL7242016

SCHEMBL7242016

Cc1c(N2CC(O)C2)c(F)cc2c(=O)c(C(=O)O)cn(-c3nc(N)c(F)cc3F)c12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.69
CYP2C9 P11712 2/20 0.69
KCNH2 Q12809 3/20 0.47
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
EPHA2 P29317 1/20 0.42
FLT4 P35916 1/20 0.42
GSK3B P49841 1/20 0.42
RARB P10826 1/20 0.42
TBXAS1 P24557 1/20 0.42
SLC6A3 Q01959 1/20 0.42
LMNA P02545 2/20 0.42
HPGD P15428 2/20 0.41
HSD17B10 Q99714 2/20 0.41
KMT2A Q03164 1/20 0.41
POLB P06746 1/20 0.41
XBP1 P17861 1/20 0.41
NFKB1 P19838 1/20 0.41
HTT P42858 1/20 0.41
NFKB2 Q00653 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7851011 0.93 CYP3A4 (0.80) CYP3A4CYP2C9KCNH2ALDH1A1EPHA2
SCHEMBL7249410 0.93 CYP3A4 (0.71) CYP3A4CYP2C9KCNH2KDM4EALDH1A1
Delafloxacin SCHEMBL294694 0.89 CYP3A4 (0.86) CYP3A4CYP2C9KDM4EALDH1A1EPHA2
SCHEMBL7851193 0.89 CYP3A4 (0.69) CYP3A4CYP2C9KDM4EALDH1A1EPHA2
Delafloxacin SCHEMBL29379152 0.89 CYP3A4 (0.86) CYP3A4CYP2C9KDM4EALDH1A1EPHA2
Delafloxacin SCHEMBL29356726 0.89 CYP3A4 (0.86) CYP3A4CYP2C9KDM4EALDH1A1EPHA2
Delafloxacin SCHEMBL441203 0.88 CYP3A4 (0.85) CYP3A4CYP2C9KDM4EALDH1A1EPHA2
Delafloxacin SCHEMBL29631821 0.88 CYP3A4 (0.85) CYP3A4CYP2C9KDM4EALDH1A1EPHA2
SCHEMBL2915100 0.88 CYP3A4 (0.63) CYP3A4CYP2C9KCNH2KDM4EALDH1A1
SCHEMBL2921140 0.88 CYP3A4 (0.63) CYP3A4CYP2C9KCNH2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6586420-B1 Photostable bactericides WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2003-07-01 US claimed
EP-1219618-A1 QUINOLINECARBOXYLIC ACID DERIVATIVE OR ITS SALT WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2002-07-03 EP claimed
US-20110159049-A1 PHARMACEUTICAL COMPOSITION DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-06-30 US disclosed
US-6586420-B1 Photostable bactericides WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2003-07-01 US disclosed
US-6586420-B1 Photostable bactericides WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2003-07-01 US disclosed
EP-1219618-A4 QUINOLINECARBOXYLIC ACID DERIVATIVE OR ITS SALT WAKUNAGA PHARMA CO LTD (JP) 2002-09-18 EP disclosed
EP-1219618-A1 QUINOLINECARBOXYLIC ACID DERIVATIVE OR ITS SALT WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2002-07-03 EP disclosed
EP-1219618-A1 QUINOLINECARBOXYLIC ACID DERIVATIVE OR ITS SALT WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2002-07-03 EP disclosed
WO-2001017991-A1 QUINOLINECARBOXYLIC ACID DERIVATIVE OR ITS SALT WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2001-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110159049-A1 PHARMACEUTICAL COMPOSITION TAS2R5, TAS2R60, TAS2R16 CYP3A4 376/4885CYP2C9 657/4885KCNH2 1834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.